Abstract
An HIV-vaccine consisting of a DNA prime, recombinant fowlpox virus (rFPV) boost was evaluated in a double-blind placebo controlled trial. One milligram of pHIS-HIV-B expressing mutated gag, pol, env, vpu, tat and rev was administered at weeks 0 and 4 boosted by 5 x 10(7) pfu rFPV-HIV-B expressing gag/pol at week 8. The vaccine regimen was safe, but there was no difference between vaccine (n = 18) and placebo recipients (n = 6) for Gag or Pol-specific T-cell immune responses at week 9.
Publication types
-
Clinical Trial, Phase I
-
Randomized Controlled Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / adverse effects
-
AIDS Vaccines / immunology*
-
Adolescent
-
Adult
-
Double-Blind Method
-
Female
-
Fowlpox virus / immunology*
-
HIV-1 / immunology*
-
Humans
-
Immunity, Cellular
-
Interferon-gamma / biosynthesis
-
Lymphocyte Activation
-
Male
-
Middle Aged
-
T-Lymphocytes / immunology
-
Vaccines, DNA / adverse effects
-
Vaccines, DNA / immunology
Substances
-
AIDS Vaccines
-
Vaccines, DNA
-
Interferon-gamma